OptiNose Executives
| OPTNDelisted Stock | USD 9.60 0.07 0.72% |
OptiNose employs about 127 people. The company is managed by 12 executives with a total tenure of roughly 24 years, averaging almost 2.0 years of service per executive, having 10.58 employees per reported executive. Analysis of OptiNose's management performance can provide insight into the firm performance.
| Peter Miller CEO CEO, Director |
OptiNose |
OptiNose Management Team Effectiveness
The company has return on total asset (ROA) of (0.0997) % which means that it has lost $0.0997 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (10.505) %, meaning that it created substantial loss on money invested by shareholders. OptiNose's management efficiency ratios could be used to measure how well OptiNose manages its routine affairs as well as how well it operates its assets and liabilities.The market capitalization of OptiNose is $97.22 Million. The majority of OptiNose outstanding shares are owned by third-party entities. These institutional holders are usually referred to as non-private investors looking to secure positions in OptiNose to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in OptiNose. Please pay attention to any change in the institutional holdings of OptiNose as this could imply that something significant has changed or is about to change at the company. Note, that even with negative profits, if the true value of the company is larger than the current market value, you may still be able to generate positive returns on investment in this company.
Some institutional investors establish a significant position in stocks such as OptiNose in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of OptiNose, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.
OptiNose Workforce Comparison
OptiNose is regarded fifth in number of employees category among its peers. The total workforce of Health Care industry is now estimated at about 18,590. OptiNose maintains roughly 127 in number of employees contributing less than 1% to equities under Health Care industry.
The company has Profit Margin (PM) of (0.37) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.41) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.41. OptiNose Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific OptiNose insiders, such as employees or executives, is commonly permitted as long as it does not rely on OptiNose's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, OptiNose insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
OptiNose Notable Stakeholders
An OptiNose stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as OptiNose often face trade-offs trying to please all of them. OptiNose's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting OptiNose's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Peter Miller | CEO, Director | Profile | |
| MPH MD | CEO Director | Profile | |
| Jonathan Neely | Vice President - Investor Relations and Business Operations | Profile | |
| Anthony Krick | Vice Officer | Profile | |
| Michele MBA | VP CFO | Profile | |
| Terence Kohler | Chief Officer | Profile | |
| Paul Spence | Chief Officer | Profile | |
| John Messina | Sr Affairs | Profile | |
| Karen Brophy | Chief Resources | Profile | |
| Michael Esq | Chief Secretary | Profile | |
| Victor Clavelli | Chief Officer | Profile | |
| Per MD | CoFounder AS | Profile |
About OptiNose Management Performance
The success or failure of an entity such as OptiNose often depends on how effective the management is. OptiNose management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of OptiNose management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the OptiNose management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. OptiNose, Inc. was founded in 2000 and is headquartered in Yardley, Pennsylvania. Optinose operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 189 people.
OptiNose Workforce Analysis
Traditionally, organizations such as OptiNose use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare OptiNose within its industry.OptiNose Manpower Efficiency
Return on OptiNose Manpower
| Revenue Per Employee | 616K | |
| Revenue Per Executive | 6.5M | |
| Net Loss Per Employee | 169.6K | |
| Net Loss Per Executive | 1.8M |
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.
Other Consideration for investing in OptiNose Stock
If you are still planning to invest in OptiNose check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the OptiNose's history and understand the potential risks before investing.
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets |